BlueOcean and CMAX Sign Joint Venture Agreement

BlueOcean NutraSciences Inc. (“BlueOcean”) (TSX VENTURE:BOC) is pleased to announce the signing of a Joint Venture Agreement (“JV”) with CMAX Technologies Inc (“CMAX”). The JV (2453969 Ontario Inc.), combines BlueOcean’s omega-3/astaxanthin oil ingredients supply and marketing expertise with CMAX’s proprietary formulation technology to produce slow-release omega-3 tablets from a variety of oils including shrimp, krill, algal and fish oils. These tablets target the rapidly growing omega-3 and astaxanthin dietary supplements markets.

Tablet formulation development work is underway with commercially ready slow-release tablet samples from omega-3 fish oils expected in March 2015 from CMAX’s tableting facility in Toronto, Canada. The JV will also produce tablets from BlueOcean’s supply of shrimp oil ingredients, as well as provide custom tablet formulations for customers using their preferred omega-3 fish, krill and algal oils.

Slow-release tableting of omega-3/astaxanthin oils is a new formulation for these essential dietary supplements which are currently only available in standard gel caps. CMAX’s tableting technology is currently being used in the pharmaceutical industry for the formulation of a number of BCS class 2 drugs currently awaiting FDA approval. These slow-release omega tablets will be much smaller and easier to swallow than standard omega-3 gel caps.

CMAX’s patent-pending slow-release technology has been proven to result in dramatic bio-availability increases in pharmaceutical applications. The slow-release omega-3 tablets will also be formulated for maximum bio-availability versus standard omega-3 fish oil gel caps.

The tiny omega-3 fish oil tablets seen above were made by the JV using powdered omega-3 fish oil. They contain approximately 150 mg EPA and 125 mg DHA. The JV will also offer custom formulation for customers from their preferred fish, krill and algal oils, or will license its formulation technology to those customers who prefer to produce their own slow-release tablets.

Also seen above is a sample of BlueOcean’s AstaShrimp™ oil that will be sold as a bulk ingredient from BlueOcean’s other joint venture, 70717 Newfoundland and Labrador Ltd as well as be used to make two slow-release shrimp oil tablets in the JV.

The first shrimp oil tablet, Pacific Pure™, will be made from BlueOcean’s Pacific AstaShrimp™ and will contain over 2 mg astaxanthin, 125 mg phospholipids 40 mg EPA and 30 mg DHA. Both the Pacific AstaShrimp™ bulk oil and Pacific Pure™ tablets will be available for commercial production and sale in March 2015.

The second shrimp oil tablet, Arctic Pure™, will be made from BlueOcean’s Northern AstaShrimp™ oil extracted from the shrimp by-products of Marine Stewardship Council certified Canadian Northern cold water shrimp. Arctic Pure™ will contain over 3 mg astaxanthin, 150 mg phospholipids, 70 mg EPA and 40 mg DHA. Northern AstaShrimp™ bulk oil and Arctic Pure™ tablets can be ordered now.


View original article at: BlueOcean and CMAX Sign Joint Venture Agreement


Leave a Reply